Navigation Links
New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
Date:7/8/2008

SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled Thought Leader Insight & Analysis: Rheumatoid Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress in developing biological and small molecule regimens for the treatment of early RA.

According to this report, the key change in practice occurring in the treatment of RA is the push toward earlier diagnosis and treatment, which is associated with more durable remission. New biomarkers and approaches to cellular imaging in early disease are also being investigated.

"Our Panel sheds light on which companies are likely to be positioned to capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In addition, they offer predictions on how tocilizumab, certolizumab and golimumab will compete with the established biologicals, and how the current market leaders are positioning to defend their brands in the RA space. Their discussion will provide essential strategic and competitive insight for anyone with a stake in this market."

The report also addresses pain management in RA, provides a postmortem on the rituximab non-renal lupus trial, and discusses the most meaningful clinical developments related to the following mechanisms: Anti-TNF, Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase, JAK, Syk, PDE5, and more.

Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma, Pfizer, Roche/Chugai, Roche/Genentech, Sanofi-Aventis/Regeneron, UCB, Vertex and Wyeth/Trubion.

MedPredict conducted in-depth, primary interviews with leading rheumatologists from North America and Europe to provide the basis for this report.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict Market Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
2. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
3. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
4. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
5. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
6. Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report
7. Galaxy Nutritional Foods Reports FY2008 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
10. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
11. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... has an active R&D program for the development of future ... has a unique research and development center in ... Control products. Stockton has a variety ... guidelines, and is active in more than 35 counties worldwide. ... Stockton,s flagship product Timorex Gold ® is ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ., ... interactive FDA compliance training course, Writing Effective SOPs (Standard ... interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step by ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
Breaking Biology Technology:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
Breaking Biology News(10 mins):